Project Grant R50CA305057
Award Date 8/11/25
Completion Date 7/31/30
Dollars Obligated $123K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $197,518 to The Children's Hospital of Philadelphia (CHOP) to address barriers to conducting clinical trials for patients with rare tumors. The awardee, who serves as Chair of the Children's Oncology Group (COG) Rare Tumor Disease Committee and Study Chair for three COG clinical trials, will use the funding to: Expand the availability of rare tumor clinical trials within COG,...
- This federal Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports efforts by a Columbia University researcher to develop and implement NCI-sponsored cancer clinical trials at the NCI-designated Herbert Irving Comprehensive Cancer Center (HICCC). The $193,926 award, with a project period from September 1, 2025 to August 31, 2030, will enable the researcher to: (1) develop novel HICCC investigator-led trials for...
- The National Cancer Institute (NCI) awarded a $361,695 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Oklahoma Health Sciences Center (OUHSC) for the period of September 1, 2025 to August 31, 2029. The grant aims to: 1) Leverage novel mHealth applications to boost enrollment in NCI-sponsored clinical trials, 2) Promote representative clinical trial enrollment from the local catchment area population, 3) Expand Veteran access to NCI trials, and 4)...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $195,180.00 to The Trustees of the University of Pennsylvania (UEI: GM1XX56LEP58) to conduct research on noninvasive assessment of isocitrate dehydrogenase (IDH) mutation status in intrahepatic cholangiocarcinoma (ICCA). This research aims to develop improved diagnostic capabilities for ICCA, which is the second most common primary liver cancer with a very poor prognosis. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $552,763 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on KAT6A as a novel therapeutic target for the treatment of high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC). The research aims to characterize the epigenetic changes induced by KAT6 inhibitors,...
- This federal Project Grant award of $988,224.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the University of California, San Diego's research program focused on advancing treatment for head and neck cancer patients with competing health risks through multi-center randomized trials. The principal investigator has extensive experience leading national clinical trials through the NRG Oncology cooperative group and serving as co-chair of the NCI Head and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $216,682 to The Trustees of the University of Pennsylvania to develop "tumor-site activated T cell redirecting autoantibodies" - a novel cancer immunotherapy approach. The award period runs from March 1, 2025 to February 28, 2027. The project aims to leverage a patient's own anti-tumor autoantibodies to enhance the immune system's ability to target and clear cancer cells,...
- This $110,550 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research on the mechanisms of lymphatic metastasis in pancreatic ductal adenocarcinoma. The primary aim is to investigate transient, single lymph node regulatory T cell depletion as a potential therapeutic strategy to treat lymph node metastasis. The project is being conducted by the Trustees of the University of Pennsylvania, a prominent private research university,...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $483,760 to The Trustees of the University of Pennsylvania to conduct research on understanding the role of the DCAF15 protein in acute myeloid leukemia (AML). The primary objectives are to (A) decipher the biological function of DCAF15 in myeloid development and leukemia in vivo, (B) investigate the role of cohesin acetylation in AML pathogenesis, and (C) develop small molecule...
- The University of Pennsylvania received a $597,766 Project Grant from the National Cancer Institute (CFDA Program 93.394 - Cancer Detection and Diagnosis Research) to develop methods for dual-tracer multiparametric imaging with a long-axial field-of-view PET scanner. The project aims to enable the simultaneous imaging of two different PET radiotracers in a single session, which would improve the characterization of cancer and transform precision medicine guided by molecular imaging. The 5-year...